Linda Bosserman, MD, PhD, FASCO, FACP, of City of Hope, emphasizes the need for a sustainable health care system that balances cost with care so patients can achieve the best survival and quality of life after a cancer diagnosis.
Linda Bosserman, MD, PhD, FASCO, FACP, medical oncologist and professor at City of Hope, identifies key gaps in value-based cancer care, emphasizing the need to balance cost and care to improve patient outcomes and quality of life.
She discussed this topic at length during her presentation, "Challenges of Providing Therapeutic Excellence in Our Current System," at the Institute for Value-Based Medicine (IVBM)® event last week in Garden Grove, California.
This transcript has been lightly edited for clarity.
Transcript
What gaps in the current value-based care models affect the delivery of cutting-edge therapies to patients with cancer? How can these gaps be addressed?
There are significant gaps in patients receiving high-quality personalized cancer care across the country. Some of those challenges are insurance barriers that prevent patients from getting second opinions from experts with the most knowledge about their disease and the best clinical trials that will offer new treatments that can improve outcomes. New molecular testing, it's essential that patients' tumors are tested and that patients who have inherited malignancies have those tested so their treatment plan can be comprehensive from the beginning.
In patients that have barriers, either transportation, local access, or insurance barriers to getting second opinions or opinions at centers where there are experts that can work with their local doctors, that prevents people from getting the best cancer care and thus the best survival and treatment benefits.
One of the barriers is people really understanding what value is, and it's not just the lowest cost. It's ensuring the patient has the proper diagnosis, treatment, care, and support so that you have high patient satisfaction. But you also need to have high staff satisfaction because they want to provide the best care and have the time, tools, networking, teams, and partnerships so that they know they're offering the best care to their patient.
We need our health system to be sustainable, both for payers and society. Balancing that gets you to the best outcome for the best cost. It doesn't mean the lowest cost, it means the right cost to get the proper care so that patients can have their best survival and their best quality of life after a cancer diagnosis.
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More